Stocks · News reference
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call
Rhythm Pharmaceuticals (NASDAQ:RYTM) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 1:33 PM
- Checked
- Aug 4, 2026, 1:33 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
Rhythm Pharma shares rise after U.K. expands Imcivree authorization for acquired hypothalamic obesity in adults and children 4 and older.
Read original at benzingaRhythm Pharmaceuticals Says UK MHRA Expands IMCIVREE Marketing Authorization To Acquired Hypothalamic Obesity In Patients 4 And Older, Grants Orphan Drug Designation
Read original at benzingaJP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.
Read original at benzinga